Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant
chemotherapy in locally advanced breast cancer. An addition of sequential gemcitabine and
cisplatin, also a highly active combination in this indication, may result in improvement in
pathological response and overall survival. Patients with operable breast cancer will be
treated in neoadjuvant setting with gemcitabine plus doxorubicin, followed by gemcitabine
plus cisplatin.